不同风险组新诊断前列腺癌分期中的骨闪烁显像
Bone Scintigraphy in Staging of Newly Diagnosed Prostate Cancer in Regard of Different Risk Groups.
作者信息
Sevcenco Sabina, Grubmüller Bernhard, Sonneck-Koenne Charlotte, Ahmadi Yasaman, Knoll Peter, Floth Andreas, Pokieser Wolfgang, Zandieh Shahin, Christoph Klingler Hans, Shariat Sharokh, Mirzaei Siroos
机构信息
Department of Urology, SMZ Ost, Donauspital, Vienna, Austria.
Department of Urology, University of Vienna, Austria.
出版信息
Asia Ocean J Nucl Med Biol. 2019 Spring;7(2):149-152. doi: 10.22038/AOJNMB.2019.35768.1242.
OBJECTIVES
Prostate cancer (PC) is the most common cancer in men over 50 years of age. Bone scintigraphy is still performed in many institutions at the time of primary diagnosis. We aimed to evaluate the role of bone scan in the primary staging of PC in regard of different risk groups.
METHODS
A retrospective analysis of bone scans in 296 patients (mean age 64±6 y) acquired at the time of primary diagnosis was performed in our institution. The median prostate specific antigen (PSA) was 6.73 ng/ml, all patients had a Gleason score of >5.
RESULTS
Only 11/296 patients had a positive bone scan, 1 being in the intermediate risk group, 10 in the high-risk group and none in the low-risk group according to D'Amico classification.
CONCLUSION
Our results support the few published studies that less than 10% of patients with newly diagnosed PC by biopsy would develop bone metastasis, all in the intermediate or high-risk groups. Therefore, a staging by bone scan can only be recommended in patients with intermediate or high-risk, or symptomatic patients only.
目的
前列腺癌（PC）是50岁以上男性中最常见的癌症。在许多机构，初次诊断时仍会进行骨闪烁扫描。我们旨在评估骨扫描在不同风险组PC初次分期中的作用。
方法
我们机构对296例初次诊断时进行骨扫描的患者（平均年龄64±6岁）进行了回顾性分析。前列腺特异性抗原（PSA）中位数为6.73 ng/ml，所有患者的Gleason评分均>5。
结果
根据达米科分类，296例患者中只有11例骨扫描呈阳性，其中1例属于中危组，10例属于高危组，低危组无阳性病例。
结论
我们的结果支持了少数已发表的研究，即经活检新诊断的PC患者中，不到10%会发生骨转移，且均在中危或高危组。因此，仅建议对中危或高危患者或有症状的患者进行骨扫描分期。
Zotero 插件